Publication
Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia
| dc.contributor.author | Ferreira, AM | |
| dc.contributor.author | Marques da Silva, P | |
| dc.date.accessioned | 2017-01-09T13:35:52Z | |
| dc.date.available | 2017-01-09T13:35:52Z | |
| dc.date.issued | 2016-12-10 | |
| dc.description.abstract | Statin-ezetimibe combinations are a potentially advantageous therapeutic option for high-risk patients who need additional lowering of low-density lipoprotein cholesterol (LDL-C). These combinations may overcome some of the limitations of statin monotherapy by blocking both sources of cholesterol. Recently, a fixed-dose combination with atorvastatin, one of the most extensively studied statins, was approved and launched in several countries, including the USA. Depending on atorvastatin dose, this combination provides LDL-C reductions of 50-60%, triglyceride reductions of 30-40%, and high-density lipoprotein cholesterol (HDL-C) increases of 5-9%. Studies comparing the lipid-lowering efficacy of the atorvastatin-ezetimibe combination with the alternatives of statin dose titration or switching to a more potent statin consistently showed that combination therapy provided greater LDL-C reduction, translating into a greater proportion of patients achieving lipid goals. Simvastatin-ezetimibe combinations have been shown to reduce the incidence of major atherosclerotic events in several clinical settings to a magnitude that seems similar to that observed with statins for the same degree of absolute LDL-C lowering. The atorvastatin-ezetimibe combination has also been shown to induce the regression of coronary atherosclerosis measured by intravascular ultrasound in a significantly greater proportion of patients than atorvastatin alone. Atorvastatin-ezetimibe combinations are generally well tolerated. Previous concerns of a possible increase in the incidence of cancer with ezetimibe were dismissed in large trials with long follow-up periods. In this paper, we examine the rationale for an atorvastatin-ezetimibe combination, review the evidence supporting it, and discuss its potential role in the management of dyslipidemia. | pt_PT |
| dc.description.version | info:eu-repo/semantics/acceptedVersion | pt_PT |
| dc.identifier.citation | Am J Cardiovasc Drugs. 2017 Jun;17(3):169-181 | pt_PT |
| dc.identifier.doi | 10.1007/s40256-016-0205-0 | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10400.17/2598 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Springer | pt_PT |
| dc.subject | HSM MED | pt_PT |
| dc.subject | Anticholesteremic Agents/administration & dosage | pt_PT |
| dc.subject | Atorvastatin Calcium/administration & dosage | |
| dc.subject | Cholesterol, HDL/blood | |
| dc.subject | Cholesterol, LDL/blood | |
| dc.subject | Drug Therapy, Combination/methods | |
| dc.subject | Ezetimibe/administration & dosage | |
| dc.subject | Hyperlipidemias/blood | |
| dc.subject | Hyperlipidemias/drug therapy | |
| dc.subject | Simvastatin/administration & dosage | |
| dc.title | Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.title | American Journal of Cardiovascular Drugs | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |